Saved source record
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
This is a source-metadata record last found in a complete check on Sep 25, 2026. It is not a Pependium assessment of safety or effectiveness. Check the original sources for current details, corrections and full methods.
Source status: Exact-ID Europe PMC status checked Sep 25, 2026. No retraction or correction publication-type marker was listed in that response. This does not rule out other updates.
Study metadata
- Study type
- Original study
- Study category (metadata hint)
- Human
- Published
- 2026-06-06
- Authors
- Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y
- Journal or registry
- Lancet (London, England)
- Registry study design
- Not reported
- Registry enrollment
- Not reported
- Funding agencies
- Eli Lilly and Company
- Identifiers
- DOI: 10.1016/s0140-6736(26)00967-0 · PMID: 42250575
- First found
- Sep 24, 2026
- Last found
- Sep 25, 2026
Original sources
Browse saved studies · Search live sources